Recent News

• 12.09.2025 - Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
• 12.02.2025 - Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
• 11.20.2025 - Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
• 11.17.2025 - Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
• 11.14.2025 - Ensysce Biosciences Reports Third Quarter 2025 Financial Results
• 10.10.2025 - Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
• 09.04.2025 - Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
• 08.19.2025 - Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
• 08.13.2025 - Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Recent Filings

• 12.02.2025 - DEF 14A Other definitive proxy statements
• 12.02.2025 - ARS Annual Report to Security Holders
• 12.02.2025 - S-3 Registration statement under Securities Act of 1933
• 11.21.2025 - PRE 14A Other preliminary proxy statements
• 11.17.2025 - 8-K Current report
• 11.17.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 8-K Current report
• 11.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.14.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]